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Abstract.  Background: Chronic  immune  thrombocytopenia  (ITP) is  a  condition  asso
significant morbidity; however the management options are often unsatisfactory with a portion of 
patients exhibiting a refractory-relapsing disease path despite various lines of treatment including 
splenectomy. As  a  thrombopoietin
provides a novel treatment option for patients with refractory disease.
four patients with chronic ITP, who were treated with eltrombopag as a single agent. 
Methods: Four Caucasian patients with chronic refractory ITP (2 males; 2 females) were enrolled 
in this study with a mean age of 48 years (range, 39
were  refractory  to  several  lines  of  treatment  including  steroids,  intra
vincristine, and azathioprine, one patient has also received rituximab (a monoclonal antibody that 
binds  the  CD20  antigen  expressed  by  B
eltrombopag (50-75 mg) for a median period of 
Results: After a median follow up of 20 months (range, 11
levels in two patients. One recovered a normal platelet count after 13 months, the other 34 months 
of  completion  of  treatment  with 
required. 
The other two patients also discontinued 
satisfactory  platelet  counts  above  30/nL  without  any  bleeding  complications.  Other  forms  of 
immune  therapy  were  also  ceased  in  these  two  cases.  None  of  the  four  patients  required 
splenectomy.
Conclusion: The clinical outcomes in this small cohort of patients suggests that 
have a role to play in the long term control of chronic ITP 
term  immunosuppressive  therapy.  The  beneficial  outcomes  in  our  patients  led  to  a  sustained 
elevation in platelets with no adverse effects noted when used for relatively longer periods than 
; Open Journal System 
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Chronic  immune  thrombocytopenia  (ITP) is  a  condition  asso
significant morbidity; however the management options are often unsatisfactory with a portion of 
relapsing disease path despite various lines of treatment including 
thrombopoietin receptor  agonist,  eltrombopag  (GlaxoSmithKline,  Australia) 
provides a novel treatment option for patients with refractory disease. We describe the outcomes of 
four patients with chronic ITP, who were treated with eltrombopag as a single agent. 
our Caucasian patients with chronic refractory ITP (2 males; 2 females) were enrolled 
in this study with a mean age of 48 years (range, 39–59). All patients were non
were  refractory  to  several  lines  of  treatment  including  steroids,  intravenous  immunog
vincristine, and azathioprine, one patient has also received rituximab (a monoclonal antibody that 
binds  the  CD20  antigen  expressed  by  B-lymphocytes).  All  patients  were  treated  with  oral 
75 mg) for a median period of 12 months (range, 9-16). 
After a median follow up of 20 months (range, 11-34), platelet counts recovered to normal 
levels in two patients. One recovered a normal platelet count after 13 months, the other 34 months 
of  completion  of  treatment  with  eltrombopag.  No  additional  immune  suppressive  therapy  was 
The other two patients also discontinued eltrombopag at 27 and 11 months after achievement of 
satisfactory  platelet  counts  above  30/nL  without  any  bleeding  complications.  Other  forms  of 
mmune  therapy  were  also  ceased  in  these  two  cases.  None  of  the  four  patients  required 
The clinical outcomes in this small cohort of patients suggests that 
have a role to play in the long term control of chronic ITP whilst avoiding splenectomy and long 
term  immunosuppressive  therapy.  The  beneficial  outcomes  in  our  patients  led  to  a  sustained 
elevation in platelets with no adverse effects noted when used for relatively longer periods than 
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Chronic  immune  thrombocytopenia  (ITP) is  a  condition  associated with 
significant morbidity; however the management options are often unsatisfactory with a portion of 
relapsing disease path despite various lines of treatment including 
receptor  agonist,  eltrombopag  (GlaxoSmithKline,  Australia) 
We describe the outcomes of 
four patients with chronic ITP, who were treated with eltrombopag as a single agent. 
our Caucasian patients with chronic refractory ITP (2 males; 2 females) were enrolled 
59). All patients were non-splenectomised and 
venous  immunoglobulin, 
vincristine, and azathioprine, one patient has also received rituximab (a monoclonal antibody that 
lymphocytes).  All  patients  were  treated  with  oral 
34), platelet counts recovered to normal 
levels in two patients. One recovered a normal platelet count after 13 months, the other 34 months 
eltrombopag.  No  additional  immune  suppressive  therapy  was 
ltrombopag at 27 and 11 months after achievement of 
satisfactory  platelet  counts  above  30/nL  without  any  bleeding  complications.  Other  forms  of 
mmune  therapy  were  also  ceased  in  these  two  cases.  None  of  the  four  patients  required 
The clinical outcomes in this small cohort of patients suggests that eltrombopag may 
avoiding splenectomy and long 
term  immunosuppressive  therapy.  The  beneficial  outcomes  in  our  patients  led  to  a  sustained 
elevation in platelets with no adverse effects noted when used for relatively longer periods than Mediterr J Hematol Infect Dis 2012; 4; Open Journal System 
previously reported. It is worth noting that spontaneous remission does occur with ITP and is the 
most likely cause for the favourable outcome with eltrombopag therapy. However, if eltrombopag is 
able to reduce the need for splenectomy in patients with chronic ITP then a distinct quality of care 
outcome  can  be  achieved  by  avoiding  the  recognised  short- and  long-term  complications  of 
splenectomy. Randomised controlled trials with long-term follow up are warranted.
Introduction. Immune thrombocytopenia (ITP) is an 
autoimmune condition mediated by the production of 
autoantibodies directed against platelets.
1-3 Thus in ITP 
there is a premature removal of platelets by the cells of 
the  reticulo-endothelial  system,  accelerated  platelet 
destruction  and  to  some  extent  impaired  platelet 
production.
1,2 The clinical presentation is dependent on 
the  degree  of  thrombocytopenia.  Minor  symptoms 
include easy bruising and epistaxis, however when the 
platelet  count  drops  to  below  10/nL,  severe 
spontaneous  bleeding  such  as  an  intracranial 
hemorrhage can occur.
1-3
The primary aim of ITP treatment is to maintain a 
stable platelet count at a level that prevents bleeding 
events
3-5  without  applying  the  adverse  effects  of 
immunosuppressive  medical  therapies  or  surgical 
intervention. 
Typically,  therapies  for  ITP  have  focused  on 
preventing  platelet  destruction  using  glucocorticoids, 
immunoglobulins,  immunosuppressive  agents  and 
splenectomy. However,  these  therapies  have  been 
unsuccessful up to 30-40% of patients, particularly in 
chronic refractory ITP.
3-5 It has also  been noted that 
platelet  production  is  often  suboptimal  in  ITP. 
Therefore novel therapies with thrombopoietic receptor 
agonists such as oral eltrombopag
6-9 and subcutaneous 
romiplostim
10-12 are  focusing  on  enhancing  platelet 
production and have been explored as an alternative to 
immunosuppressive therapy. 
Eltrombopag is an oral small molecule, non-peptide 
thrombopoietin (TPO) receptor agonist which binds to 
the  transmembrane  domain of  the  TPO  receptor  and 
induces  the  proliferation  of  cells  within  the 
megakaryocyte lineage.
13 As eltrombopag and TPO do 
not  bind  to  the  same  site  on  the  TPO  receptor,  and 
there is no competitive binding, therefore eltrombopag 
and TPO are able to act in conjunction with each other, 
resulting in an additive cell-signalling effect that has 
shown  efficacy  and  safety  in  patients  with  chronic 
ITP.
6-9 
Various clinical studies have been carried out with 
this novel treatment. Phase I clinical trials were first 
conducted  in  2007,  reporting  an  increase  in  platelet 
count after the administration of eltrombopag for ITP, 
with  no  adverse  reactions  occurring.  Furthermore, 
platelet function was not affected by eltrombopag.
13 A 
phase I/II study conducted in 2007 with 118 patients 
with refractory and chronic relapsing ITP demonstrated 
that most patients were able to  maintain an elevated 
platelet  count  at  higher  doses  of  eltrombopag,  and 
showed a trend towards fewer episodes of bleeding.
12
Again,  similar  positive  results  were  yielded  from  a 
multinational  phase  III  randomised,  double-blind, 
placebo-controlled  trial  of  patients  with  chronic 
ITP.
11,14
Following  the  successful  introduction  of  TPO 
receptor agonists in trials where it was used as a second 
line treatment using different guidelines,
3-5 this novel 
therapy  proved  promising  for  the  future  of  patients 
suffering from chronic refractory ITP. It demonstrated 
the potential  of  avoiding poorly  tolerated  steroids, 
immunosuppressive  therapies  and  invasive  surgical 
interventions  such  as  a  splenectomy.  If  these 
therapeutic  benefits  are  confirmed,  we  consider  it  is 
possible  that  TPO  receptor  agonists  may  one  day 
become the first line treatment for chronic refractory 
ITP.
Methods and Results. We describe four patients with 
the diagnosis of chronic ITP classified according to the 
international consensus report on the investigation and 
management  of  ITP
3 and  who  presented  to  the 
Launceston General Hospital (LGH) between January 
2008 and May 2010. Approval of the Human Ethics 
Committee  of  Tasmania,  Australia  was  gained  to 
conduct this study. 
All patients were Caucasian, over 18 years of age 
with  a  mean  age  of  48  years  (range,  39–59).  There 
were  two  males  and  two  females  and  all  had  been 
diagnosed with chronic refractory ITP for more than 6 
months  (Table  1)  and  were  experiencing  ITP 
associated bleeding. 
Each patient had a normal bone marrow aspirate at 
the  time  of  diagnosis, showing  normal  or  active 
megakaryopoeisis as reviewed by the Hematologist and 
being  consistent  with  ITP.  No  evidence  of  other 
hematological disorders such as lymphoma or Evans’ 
syndrome.  None  of  these  patients  had  evidence  of 
infection  with  Hepatitis  B  or C  virus,  or  Human 
Immunodeficiency Virus. Furthermore, a Helicobacter 
pylori infection was excluded in all subjects.
3-5
The diagnosis of chronic refractory ITP was made 
in the setting of several clinical relapses in all patients 
due  to  inadequate  control of  the  ITP  by  previous 
treatment methods.
3 Each patient had received previous 
treatment for the ITP with glucocorticoids, intravenous Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
Table 1. Patient demographic and characteristics.
Patient 1  Patient 2  Patient 3  Patient 4 
Gender Male Male Female Female
Race Caucasian Caucasian Caucasian Caucasian
Diagnosis Chronic ITP Chronic ITP Chronic ITP Chronic ITP
Age at diagnosis (years) 39 59 57 39
Bone Marrow at diagnosis Normal Normal Normal Normal
Platelet count at diagnosis 
(x10
9/L)
1 12 10 <10
lowest platelets count  1 12 5 6
Previous treatments
High dose Prednisolone / 
high-dose Dexamethasone, 
IVIG Vincristine,Rituxi-
mab 
Moderate dose 
Prednisolone 50-100mg, 
Imuran Vincristine
IVIG, Prednisolone 
moderate dose, high-dose 
Dexamethasone, 
Vincristine, Imuran
IVIG, Prednisolone 
moderate dose, high-
dose Dexamethasone
Treatment period in 
months 9 16 11 12
Dose (in mg) 50-75 50 50 50-75
Follow up post 
Eltrombopag (months)
34 27 13 11
Splenectomy  None None None None
Prednisolone moderate dose is between 25mg-75 mg, high-dose; between 500 mg to 1000mg. High-dose dexamethasone 40 mg. IVIG; 
intravenous immunoglobulin at dose of 1g/Kg body weight. 
immunoglobulin  (IVIG)  or  immune  modulators  and 
one failed treatment with rituximab. 
Patients  who  were  concomitantly  treated  with 
steroid therapy had their steroid dose tapered down to a 
complete  stop  whilst  on  the  eltrombopag  treatment.
None  of the  patients proceeded  with  splenectomy as 
they refused the procedure and opted for new therapy 
in order to control their difficult ITP. 
The therapeutic regimen in all patients was a once 
daily dose of 50 or 75 mg of eltrombopag administered 
orally. The  treatment  period  varied  between  9  to  16 
months (median, 12) and patients were followed up for 
a median period of 20 months (range, 11-34) (Table 
1).
The  patients  platelet  counts  were  measured 
regularly mostly on a weekly basis for all patients who 
were  receiving  different  treatment  lines.  In  addition, 
patient  tolerability,  drug  safety,  signs  of  bleeding, 
quality of life and any complications were recorded. 
In  two  of  the  four  patients, the  platelet  counts 
recovered  to  normal  levels  for  at  least  1  year  after 
completion of treatment with eltrombopag. No further 
immune  suppressive  therapy  was  required  and  these 
patients currently have normal platelet counts at 34 and 
13 months post eltrombopag-treatment.
The other two patients also had their eltrombopag 
discontinued  after  achievement  of  platelet  counts 
between  50-100/nL  without  any  bleeding 
complications.  In  the  meantime,  other  forms  of 
immune therapy were ceased. No patient proceeded to 
splenectomy as part of management of their refractory 
ITP (Table 1).
Within the study period of our cohort of patients in 
this report, we had investigated 47 patients with ITP at 
our hospital that were referred by either the General 
Practitioners (GP) or Emergency Department and were 
managed as the first line of treatment with steroids or 
IVIG therapy. Of these thirty patients (64%) responded 
to the first line treatment (with corticosteroids and/or 
IVIG  therapy)  and  maintained  their  platelets at  a 
satisfactory  level  with  a  platelet  count  above  30/nL, 
while 9 patients (19%) required additional courses of 
treatment  including  IVIG  with  a  good  response  and 
maintained the platelet count above 30/nL. 
Eight  patients  (17%)  developed  refractory ITP  as
defined by the International Consensus Report criteria
3
and underwent a second line treatment, in which four 
(4) patients underwent splenectomy. The four (4) non-
splenectomised patients were included in this current 
study and were treated with oral TPO-receptor agonist 
(Eltrombopag) available at the LGH as a part of the 
patient familiarization program for compassionate use 
only. Two patients who underwent splenectomy have 
recovered  from  ITP,  while  the  other  two  patients 
required  further  treatment  with  the  newly available 
TPO agonist, romiplostim (Nplate®, Amgen Australia) 
and have successfully maintained a satisfactory level of 
platelets without other forms of treatment for ITP.
Discussion. Chronic refractory ITP is understood to be 
an autoimmune disorder.
1-5 Therapeuticoptions that are 
often  successful  in  patients  with  acute  ITP  such  as 
corticosteroids, IVIG,  alkylating  agents  and 
splenectomy,  have  a  variable  effect  on  chronic 
refractory ITP.
3-5
Splenectomy is currently employed as a second line Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
therapy, however it is ineffective in about 30
the cases.
15,16 Also these therapies present an increasing 
risk  for  opportunistic  infection  and  post  surgical 
complications  during  their  treatment  courses  and 
adversely affect the overall outcomes.
16
The  human  monoclonal  antibody,  rituximab,  is  a 
chimeric, IgG1/ that is specific for the CD 20 antigen, 
expressed  on  the  surface of  B  lymphocytes  and 
employed  in  immune-mediated  disorders.
Furthermore,  complement-dependent  cytotoxicity  is 
probably one of the mechanisms of action of rituximab 
and has been proposed by some authors as the most 
important mechanism in controlling different immune 
disorders.
17 However, the success rate of rituximab in 
chronic refractory ITP remains  variable
20-40%.
3,18,19 Furthermore  in  our  study,  patient  1 
(Table  1)  received,  in  addition  to  three  different 
immunotherapies,  rituximab  without  any  response. 
Eltrombopag therapy was well tolerated without side 
effects. The platelet counts remain currently normal in 
two patients and above 30/nl in the other two despite 
discontinuation of the drug for more than 6 months and 
absence of other treatments.
In  a  literature  review  we  found  that  splenectomy 
complications  were  reported  around  12.9%  with
laparotomy and 9.6% with laparoscopy
rates  of  1.0%  with  laparotomy  and  0.2%  with 
laparoscopy.
20-22  With  TPO-receptor  agonists  in 
patients  after  splenectomy  there  is  approximately  an 
80% overall response rate.
3-5
The  International  Consensus  Report  on  ITP 
published by Provan and colleagues,
3 defined first line 
treatment with corticosteroids and/or IVIG therapy and 
anti-D.  All  patients  in  our  series  had  received  the 
former treatments while the latter treatment (Anti
not available in Australia. 
The  second  line  was  referred  to  surgical 
intervention  (splenectomy)  or  medical  management 
consisting  mainly  of  chemotherapeutic  agents  (e.g. 
vincristine,  cyclophosphamide)  in
immunomodulators (e.g. rituximab, cyclosporin A) in 
addition  to  the  novel  agents  with  TPO
agonists.  The  same  expert  review  suggested  that 
approximately  20%  of  patients  do  not  attain  a 
hemostatic  platelet  count  after  splenectomy  with  an 
additional 20% of splenectomised patients
relapsing.
3
The  American  Society  of  Hematology  (ASH)  in 
2011 published evidence-based practice guidelines for 
ITP  and  recommended  TPO  receptor  agonists  for 
patients  at  risk  of  bleeding  who  relapsed  after 
splenectomy or had a contraindication to splenectomy. 
At  the  same  time  the  expert-consensus  for  the 
standardization  of  terminology,  definitions  and 
: Open Journal System
y, however it is ineffective in about 30-40% of 
Also these therapies present an increasing 
risk  for  opportunistic  infection  and  post  surgical 
complications  during  their  treatment  courses  and 
16
an  monoclonal  antibody,  rituximab,  is  a 
that is specific for the CD 20 antigen, 
of  B  lymphocytes  and 
mediated  disorders.
17
dependent  cytotoxicity  is 
chanisms of action of rituximab 
authors as the most 
important mechanism in controlling different immune 
However, the success rate of rituximab in 
chronic refractory ITP remains  variable,being around 
Furthermore  in  our  study,  patient  1 
(Table  1)  received,  in  addition  to  three  different 
immunotherapies,  rituximab  without  any  response. 
therapy was well tolerated without side 
effects. The platelet counts remain currently normal in 
two patients and above 30/nl in the other two despite 
discontinuation of the drug for more than 6 months and 
ew  we  found  that  splenectomy 
complications  were  reported  around  12.9%  with
laparotomy and 9.6% with laparoscopy, with mortality 
rates  of  1.0%  with  laparotomy  and  0.2%  with 
receptor  agonists  in 
approximately  an 
The  International  Consensus  Report  on  ITP 
defined first line 
or IVIG therapy and 
D.  All  patients  in  our  series  had  received  the 
er treatments while the latter treatment (Anti-D) is 
The  second  line  was  referred  to  surgical 
intervention  (splenectomy)  or  medical  management 
consisting  mainly  of  chemotherapeutic  agents  (e.g. 
de)  including 
omodulators (e.g. rituximab, cyclosporin A) in 
addition  to  the  novel  agents  with  TPO-receptor 
agonists.  The  same  expert  review  suggested  that 
approximately  20%  of  patients  do  not  attain  a 
hemostatic  platelet  count  after  splenectomy  with  an 
itional 20% of splenectomised patients eventually 
The  American  Society  of  Hematology  (ASH)  in 
based practice guidelines for 
ITP  and  recommended  TPO  receptor  agonists  for 
patients  at  risk  of  bleeding  who  relapsed  after 
plenectomy or had a contraindication to splenectomy. 
consensus  for  the 
standardization  of  terminology,  definitions  and 
outcome criteria in ITP published by the International 
Working Group
5 reported that refractory ITP patients 
should meet the criteria of a failed splenectomy and 
exhibit severe ITP complications.
of patients did not undergo splenectomy, they have had 
severe ITP and failed first and second lines of medical 
treatment.
The  ITP  patients  are  pred
General Practitioners (GP) in Australia. However, they 
are  referred  to  the  Hematologist  when  the  platelet 
count  becomes  very  low,  or  when  a  bleeding 
complication occurs, or prior to surgical procedure for 
an expert opinion. Therefore, 
ITP to the LGH during the study period does not reflect 
necessarily all cases of ITP diagnosed at the same time. 
It is beyond the scope of this study to analyse all cases 
of ITP that have been referred to the same institution.
Conclusion.  In  our  case
eltrombopag  played  a  significant  role  in  these  non
splenectomised patients with chronic ITP. The results 
recorded here provide a further evidence for the long
term  control  of  chronic  ITP  without  requiring 
splenectomy.  We  also  note  that  the  newer 
thrombopoietic  agents  do not  generally  cure  patients 
with  ITP.  From  our  results,  even  though  the  patient 
subgroup is small, we believe that the achievement of 
treatment  independency  with 
related  to  the  natural  history  of  ITP  rather  than  the 
long-term  effect  of  the  TPO
maintenance  of  platelet
eltrombopag  could  be  attributed  to  a  spontaneous 
remission  that  is  not  uncommon  in  ITP.
TPO-receptor agonists may be considered an effective 
tool for obtaining safe levels of platelets waiting for a 
possible  spontaneous  remission  of
mechanisms that lead to ITP.
Our results may indicate that patients with chronic 
and refractory ITP should be considered for treatment 
with  thrombopoietin  receptor  agonists  before 
proceeding  with  an  irreversible  invasive  surgical 
procedure  such  as  splenectomy.  Employing 
thrombopoietin receptor  agonists  in  this  cohort  of 
patients  may  avoid  the  known  risks  associated  with 
splenectomy including general anesthesia risks, risk of 
complications during and after the procedure as well as 
increasing  susceptibility  for  long
Further  randomised  trials  to  address  this  issue  are 
warranted. 
Acknowledgments.  Eltrombopag  was  supplied  by 
GlaxoSmithKline (GSK), Australia as a part of patient 
familiarization programme. 
outcome criteria in ITP published by the International 
reported that refractory ITP patients 
should meet the criteria of a failed splenectomy and 
exhibit severe ITP complications. Although our cohort 
of patients did not undergo splenectomy, they have had 
severe ITP and failed first and second lines of medical 
The  ITP  patients  are  predominantly  managed  by 
General Practitioners (GP) in Australia. However, they 
are  referred  to  the  Hematologist  when  the  platelet 
becomes  very  low,  or  when  a  bleeding 
or prior to surgical procedure for 
an expert opinion. Therefore, the 47 referred cases with 
ITP to the LGH during the study period does not reflect 
necessarily all cases of ITP diagnosed at the same time. 
It is beyond the scope of this study to analyse all cases 
been referred to the same institution.  
In  our  case-series,  we  believe  that 
eltrombopag  played  a  significant  role  in  these  non-
splenectomised patients with chronic ITP. The results 
recorded here provide a further evidence for the long-
term  control  of  chronic  ITP  without  requiring 
lenectomy.  We  also  note  that  the  newer 
thrombopoietic  agents  do not  generally  cure  patients 
with  ITP.  From  our  results,  even  though  the  patient 
subgroup is small, we believe that the achievement of 
treatment  independency  with  eltrombopag  may  be 
the  natural  history  of  ITP  rather  than  the 
term  effect  of  the  TPO-receptor  agonist.
3 The 
maintenance  of  platelet-count  after  stopping 
ltrombopag  could  be  attributed  to  a  spontaneous 
remission  that  is  not  uncommon  in  ITP.
1-5 The  new 
receptor agonists may be considered an effective 
tool for obtaining safe levels of platelets waiting for a 
possible  spontaneous  remission  of immune 
mechanisms that lead to ITP.
3-5
Our results may indicate that patients with chronic 
and refractory ITP should be considered for treatment 
with  thrombopoietin  receptor  agonists  before 
proceeding  with  an  irreversible  invasive  surgical 
procedure  such  as  splenectomy.  Employing 
receptor  agonists  in  this  cohort  of 
patients  may  avoid  the  known  risks  associated  with 
splenectomy including general anesthesia risks, risk of 
complications during and after the procedure as well as 
increasing  susceptibility  for  long-term  infections.
20-23
Further  randomised  trials  to  address  this  issue  are 
Eltrombopag  was  supplied  by 
, Australia as a part of patient 
familiarization programme. Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
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